What is thymosin alpha-1?
A beginner-friendly introduction to thymosin alpha-1 (thymalfasin, Zadaxin): what it is, how it rebalances the immune system, why it is not TB-500, and the honest state of its evidence.
An immune-rebalancing peptide, registered abroad and misunderstood everywhere
Thymosin alpha-1 (Tα1, generic name thymalfasin, brand Zadaxin) is a 28-amino-acid peptide the body cuts from a larger nuclear protein. Rather than switching immunity on like a stimulant, it works like a rheostat, nudging a dysregulated immune system back toward balance.
That subtlety is the whole story. Its mechanism is genuinely well studied, it is sold as a registered medicine outside the United States, and yet its biggest, best-designed trials have often come up neutral. This unit sets the honest foundation, including why it is constantly and wrongly confused with TB-500.
What you'll learn
- What thymosin alpha-1 actually is: a 28-amino-acid prothymosin alpha fragment, not TB-500
- How it rebalances immunity through T-cell maturation, Th1 polarization, and dendritic-cell TLR signaling
- What the hepatitis B trials do and do not show, and where pivotal trials came up neutral or negative
- Its regulatory reality: one verifiable foreign registration, no FDA approval, and no authorization for US compounding
What this course covers
11 units take you from the essentials to an in-depth understanding.
- 01 What is thymosin alpha-1? An immune-rebalancing peptide, registered abroad and misunderstood everywhere free
- 02 Discovery and origins From a crude thymus extract to a synthetic immune drug paid
- 03 The molecule: structure and chemistry Twenty-eight acidic residues with an acetyl cap paid
- 04 How it works: the immune mechanism Maturing T cells, priming dendritic cells, rebalancing tone paid
- 05 Not TB-500: the mandatory disambiguation Same prefix, different molecule, different everything paid
- 06 The hepatitis evidence A small, delayed, and uncertain signal paid
- 07 Critical illness: sepsis and COVID-19 Where the best trials turned neutral paid
- 08 Cancer adjuvant and vaccine support Immune support around cancer and vaccination paid
- 09 Dosing and administration How it is given, and why the numbers are education only paid
- 10 Safety, side effects and regulation Well tolerated in trials, unauthorized at the pharmacy paid
- 11 Final exam and certification Pass the final exam to earn your certificate of completion. Exam
Key terms
What thymosin alpha-1 actually is
Thymosin alpha-1 is a small fragment of a much larger protein. The body cuts the first 28 amino acids off a nuclear protein called prothymosin alpha, and the native peptide carries an acetyl cap on its first amino acid, a serine. That short, acidic, acetylated peptide is Tα1, and the marketed drug is a chemically synthesized copy of it.
Two features define it. First, it is a fragment, not a standalone gene product: it is cut from a larger nuclear protein, prothymosin alpha. Second, it behaves as a signal, priming immune cells rather than acting as a classic hormone or growth factor. Keep both in mind, because they explain its gentle, wide-ranging effects.
AdvancedWhy "a fragment of prothymosin alpha" matters
Prothymosin alpha is a protein linked to chromatin remodeling and to cell growth, and it is thought to sit inside the cell nucleus. Tα1 corresponds to its N-terminal 28 residues, released by a lysosomal asparaginyl endopeptidase identified as legumain, and the same enzyme cuts out a 35-residue sibling fragment, thymosin alpha-11. In recombinant work, only a fraction of the prothymosin alpha made in bacteria carried the acetyl group, so the acetylated Tα1 it released had to be purified out; that purified form matched the chemically synthesized peptide in mass.
A rheostat, not a switch
The single most important idea in this course is that Tα1 does not just boost immunity. It behaves more like a rheostat than an accelerator: it can augment a deficient response, and one line of work shows it also building a regulatory environment that balances inflammation and tolerance. No specific receptor has been found for it, and its effects are described as pleiotropic, running through several pathways.
Because it works across several levers at modest strength, Tα1 is best understood as a context-dependent balancer. That breadth is why it has been trialed in such different diseases, and also why pinning down a single clean effect has been so hard. Hold that tension; it recurs throughout the course.
AdvancedWhy "restore balance" is not a cop-out
A blunt stimulant would be dangerous in an already inflamed patient and useless in an immunosuppressed one. The rheostat model predicts the opposite: benefit concentrated where the immune system is off-balance (sepsis-related immune paralysis, lymphopenia, weak vaccine responses in the elderly) and little effect in a healthy, balanced system. That prediction is testable, and later units check it against real trial data.
It is not TB-500
The most common error in peptide-community content is treating thymosin alpha-1 and TB-500 as versions of the same thing. They are not. The World Anti-Doping Agency's prohibited list names TB-500 among the derivatives of thymosin beta-4, a completely different peptide with a different length, sequence, mechanism, and purpose. A full unit covers this later; the preview matters now so nothing that follows is misread.
The only real link is history: both were first separated from the same crude thymus extract and both carry the word "thymosin." Beyond that shared name, they are different molecules doing different jobs. Calling them interchangeable or stackable equivalents is simply a factual error.
AdvancedWhere the shared name came from
Thymosin research began in the 1960s, and from 1972 Allan Goldstein and colleagues prepared "thymosin fraction 5," a partially purified calf-thymus extract. Several distinct peptides were later isolated from it and tested separately, among them thymosin alpha-1, prothymosin alpha, parathymosin and thymosin beta-4. Tα1 was sequenced in 1977 and thymosin beta-4 in 1981, out of that same program, which is the entire basis of the confusion.
Registered abroad, not approved in the US
Tα1 occupies an unusual regulatory position, and the usual summary of it is not quite right. Reviews repeat that Zadaxin / thymalfasin is approved in more than 35 countries for hepatitis B and C, but none of them points to a regulatory record for it. When the FDA reviewed the manufacturer's own claims in 2024, which its 2014 annual report puts as approval across regions of Asia-Pacific, Latin America, Eastern Europe and the Middle East, the FDA said it was unable to independently verify them. The one foreign registration that can be read in a regulator's own document is the Italian one, granted in 1996, and its authorized use is as an adjuvant to influenza vaccination in immunocompromised adults, not hepatitis. In the United States there is no marketing approval at all, only orphan designations, and compounded products containing it are marketed online.
This split is not a technicality. An orphan designation is a development incentive, not an efficacy endorsement, and it is frequently misrepresented as "FDA recognition." Where Tα1 is registered, a patient gets a controlled product; where it is not, a buyer gets an unverified vial. Same molecule, very different guarantees.
AdvancedWhat an orphan designation actually grants
A US orphan-drug designation is a development incentive for a rare-disease indication. It says nothing about whether the drug works or is approved for sale. The FDA's orphan database holds four designations for thymalfasin, for chronic active hepatitis B, DiGeorge anomaly with immune defects, hepatocellular carcinoma and stage IIb to stage IV malignant melanoma. Every one of the four carries the same approval line, not FDA approved for the orphan indication, so any claim that the peptide is "FDA-recognized" is misleading. What designation does grant, by the FDA's own page, is incentives: tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval, through a process separate from seeking approval.
The honest evidence ceiling
Before any deeper science, here is the honest picture, tiered by strength. The mechanism has been studied in several laboratories, mostly in mouse and cultured-cell systems. The hepatitis B use, the indication the manufacturer reports registrations for, rests on small, older randomized trials that disagree with one another, and a Cochrane review rates the certainty of that evidence low to very low. And the high-profile sepsis and COVID-19 claims are where the evidence thins out: the largest blinded sepsis trial was neutral, and the COVID-19 record is mostly observational and mixed. Keeping these three tiers strictly apart, rather than blurring them into one hopeful story, is the whole point of this course.
This course is education, not medical advice, and nothing here is a recommendation to use thymosin alpha-1. It is not FDA-approved for any use in the United States.
Popular claims, checked
A few specific claims you will meet online, held against the evidence tiers above. Notice the pattern: the claims are usually not fabricated so much as rounded up, taking a modest, single-region, or observational signal and presenting it as settled fact.
Reading each claim against its actual evidence tier is exactly the skill this course builds. Some, like the excellent tolerability, hold up reasonably well; others, like the sepsis and TB-500 claims, collapse on contact with the primary literature. The next units give you the detail to do this yourself.
AdvancedWhy "well tolerated" is the sturdiest claim here
Across the hepatitis and cancer record, Tα1 is repeatedly described as well tolerated, with local irritation, redness or discomfort at the injection site the most common reactions, and in a head-to-head hepatitis B trial it was well tolerated by all patients, unlike interferon. That tolerability is one of its genuinely strong points. The honest caveat is that tolerability is not efficacy, and long-term, repeated-course Western safety data remain limited.